Today we announced our Q1 FY'25 financial results. For more details click here: https://bit.ly/3WoXd5x #WeAreDrReddys #GoodHealthCantWait
Dr. Reddy's Laboratories
Pharmaceutical Manufacturing
Hyderabad, TS 1,207,968 followers
We accelerate access to affordable and innovative medicines because Good Health Can’t Wait.
About us
Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY) is a global pharmaceutical company headquartered in Hyderabad, India. Established in 1984, we are committed to providing access to affordable and innovative medicines. Driven by our purpose of ‘Good Health Can’t Wait’, we offer a portfolio of products and services including APIs, generics, branded generics, biosimilars and OTC. Our major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Our major markets include – USA, India, Russia & CIS countries, China, Brazil and Europe. As a company with a history of deep science that has led to several industry firsts, we continue to plan ahead and invest in businesses of the future. As an early adopter of sustainability and ESG actions, we released our first Sustainability Report in 2004. Our current ESG goals aim to set the bar high in environmental stewardship; access and affordability for patients; diversity; and governance. For more information, log on to: www.drreddys.com. Caution Notice: Dr. Reddy's has been made aware of candidates receiving fraudulent job opportunities from unauthorised recruiting agencies or people impersonating Dr. Reddy's leaders. These fraudulent jobs may be advertised on employment sites or mimic our careers site and company email addresses. Please know that Dr. Reddy's Laboratories has no affiliation or connection to these situations. Dr. Reddy's (and its associated/group companies) follows a formal recruitment process through its own HR department. Please report immediately in case you suspect a fraudulent job. You may raise your concern by: Accessing https://drreddys.ethicspoint.com. Calling on the hotline number. List of hotline numbers are available in https://drreddys.ethicspoint.com. The hotline is available 24x7 in multiple languages. Writing to [email protected] or [email protected].
- Website
-
http://www.drreddys.com
External link for Dr. Reddy's Laboratories
- Industry
- Pharmaceutical Manufacturing
- Company size
- 10,001 employees
- Headquarters
- Hyderabad, TS
- Type
- Public Company
- Founded
- 1984
- Specialties
- pharmaceutical, specialty, biogeneric, API, and generic formulations
Locations
Employees at Dr. Reddy's Laboratories
Updates
-
As the 2024 Olympics begin today, three cheers for our colleague, Obiageri amaechi based in our Princeton, New Jersey office, who will represent Nigeria in Women’s Discus Throw at the Paris 2024 Olympics! Obi is a Management Trainee with our Specialty Rx Marketing team in Princeton. Obi graduated from Princeton University in 2021 where she was a two-time All-American and Ivy League Record holder in women’s discus throw. As a Nigerian-American discus throw athlete, she is set to represent Nigeria at the 2024 Olympics in Paris. Her past achievements range from the African Championships, Commonwealth Games to the World Athletic Championship and African Games. Aside from sport and work, Obi enjoys cooking Nigerian dishes and making baked goods for her teammates. As the athletes take the stage today to stand for the values of excellence, respect and friendship, it is a proud moment for all of us at Dr. Reddy’s globally. We stand with Obi and wish her the best! #WonderWomenOfDrReddys #HumansofDrReddys #ParisOlympics #Olympics2024 #WeAreDrReddys
-
-
Have you registered yet? Participate in the second edition of our campus case study competition, 'Destination Dr. Reddy's'. For the second year in a row, we're eager to invite and engage with bright young minds and future leaders of healthcare from management, engineering, and pharmacy universities to participate in our case study competition to solve real-life healthcare challenges with fresh, innovative thinking. Register now: https://bit.ly/3y1A3dr. Exciting prizes and PPI opportunities for internship are up for grabs! #GoodHealthCantWait #WeAreDrReddys #CaseStudyCompetition
-
-
Dr. Reddy's Laboratories reposted this
We are pleased to announce that US FDA has approved IND for our asset AUR-112, a potent and selective inhibitor of MALT1, being developed for the treatment of lymphoid malignancies. With desirable free fraction and potency in human whole blood assay, AUR-112 may add clinical value to patients. This milestone is a testament to the team's hard work and dedication, reaffirming our commitment to developing innovative therapeutics for cancer patients worldwide. #MALT1 #Oncology #Cancer #DrugDiscovery #INDapprovals #CancerTherapies #CancerDrugs #FDAapprovals #Lymphoma #CancerTreatment #IndiaDrugDiscovery #OncologyPipeline #CancerDrugPipeline #NovelTherapeutics #OncologyTargets
-
-
American zoologist and experimental embryologist Ross Granville Harrison was the first person to grow animal cells outside the body, in 1907. He adapted the “hanging drop” method from bacteriology for use with tissue culture, and successfully cultured frog nerve cells in clotted frog lymph. This method is now well adapted and has become a beacon for life science research advancements. #didyouknow #culturecells #lifescience #bacteriology #drugresearch
-
-
𝗔𝗱𝗱𝗿𝗲𝘀𝘀𝗶𝗻𝗴 𝗗𝗶𝗮𝗿𝗿𝗵𝗲𝗮 𝗖𝗵𝗮𝗹𝗹𝗲𝗻𝗴𝗲𝘀: 𝗜𝗻𝘁𝗲𝗴𝗿𝗮𝘁𝗶𝗻𝗴 𝗛𝗲𝗮𝗹𝘁𝗵, 𝗜𝗻𝗱𝘂𝘀𝘁𝗿𝘆 & 𝗣𝗼𝗹𝗶𝗰𝘆 𝗣𝗲𝗿𝘀𝗽𝗲𝗰𝘁𝗶𝘃𝗲𝘀 Join us for the 3rd episode of our series on "Addressing Diarrhea Challenges. This insightful discussion will take place on 24th July 2024 from 2:30 PM to 3:30 PM. Don't miss out on this important event aimed at tackling Diarrhea issues from health, industry, and policy perspectives. 𝗥𝗲𝗴𝗶𝘀𝘁𝗲𝗿 𝗻𝗼𝘄: https://lnkd.in/g6x3-7pt 𝗠𝗲𝗲𝘁 𝗧𝗵𝗲 𝗘𝗺𝗶𝗻𝗲𝗻𝘁 𝗦𝗽𝗲𝗮𝗸𝗲𝗿𝘀: Dr. Jayesh Lele, Immediate Past National Vice President and Past Hon. Secretary General, Indian Medical Association Dr. K. Madan G., Advisor - Public Health Administration, NHSRC- Ministry of Health and Family Welfare, Government of India Dr. Somnath Singh (PhD), Deputy Director, UN Global Compact Network India Mr. Anuj Reddy, Venture Head - Digital Health, Horizon 2, Dr. Reddy's Laboratories Dr. Manisha Khurana, Founder, NextEdge- Precision Medicine Insights Pinky Chahar Khushbu Sharma #DistressIndiaDiarrhea #Healthcare #Policy #Challenges
Virtual Session on Addressing Diarrhea Challenges
www.linkedin.com
-
Conheça seu corpo, ouça seus sinais. 🗣️👂 Os sintomas do câncer de garganta e laringe podem ser sutis. Fique atento e não hesite em procurar ajuda médica. Fonte: Instituto Nacional de Câncer (INCA) - https://lnkd.in/eGFuNiiw R1269956-BR-CO-01072024-0058 - Material destinado para o público geral - Jul-24 SAC 0800 87 89 055 [email protected] #julhoverde #drreddys #drreddy's #goodhealthcant wait #goodhealthcan'twait #AutoCuidado #SaúdeEmFoco #JulhoVerde
-
-
Pleased to share that we have been recognised at the e4m Indian PR and Corporate Communications Awards (IPRCCA) with the bronze in the 'Healthcare Marketing Campaign' category for our campaign 'Tension Mat Lo'. It is estimated that at least one in four adults in India has hypertension, but only about 12% of them have their blood pressure (BP) under control. The Government of India has set a target of 25% relative reduction in hypertension prevalence by 2025*. Drawing on our three decades of expertise in hypertension management in India, we launched a brief focused campaign last year to raise awareness and deliver crucial messages on blood pressure control to patients, our own near and dear ones, healthcare professionals, and even our colleagues - both those currently affected by hypertension, and those at risk. The use of a highly regarded brand ambassador and a universally appealing tagline in #TensionMatLo were meant to encourage individuals to pause, listen to their bodies, and take charge of their health through proactive hypertension management, reminding individuals that neglect can lead to serious complications. #WeAreDrReddys #GoodHealthCantWait #TensionMatLo Source: https://lnkd.in/dE8hMv3R
-
-
Pleased to share that we have entered into a non-exclusive patent licensing agreement with Takeda Pharmaceutical Company Limited to commercialise Vonoprazan tablets in India. For over three decades, patients and healthcare professionals have trusted our products in the gastrointestinal segment including well-known brands such as Omez®, Razo™ and others. Leveraging our expertise in this therapy area, we are pleased to make the first-in-class drug Vonoprazan (Vono™) available to patients in India. The non-exclusive patent licensing agreement with Takeda is part of our continuous efforts to make innovative medicines available to patients in India through strategic collaborations to meet unmet needs and enhance standard of care. To know more click here: https://lnkd.in/g4zTNXBq #WeAreDrReddys #GoodHealthCantWait #SDG3
-
-
The video of our engaging CEO Panel Discussion at the 9th Global Pharmaceutical Quality Summit 2024 is now available! The panel discussion, titled 'Blueprinting for the Future: Charting out the Next Decade of Pharma Quality & Operations', featured distinguished speakers: Umang Vohra, Managing Director & Global CEO, Cipla, Prasad G V, Co-Chairman and Managing Director, Dr. Reddy's Laboratories, Nilesh Gupta, Managing Director, Lupin, Dilip Shanghvi, Chairman and Managing Director, SUN PHARMA, and Pankaj Patel, Chairman, Zydus Group. The session was moderated by Sathya Prathipati, Senior Partner & Lead, Life Sciences Practice in Asia, McKinsey & Company. This discussion paves the way for continued excellence in pharma quality and operations. Click on the link to view the session: https://lnkd.in/dE8zjqAm
-